{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:00:16Z","timestamp":1790672416198,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,15]]},"DOI":"10.1093\/cid\/cit346","type":"journal-article","created":{"date-parts":[[2013,5,24]],"date-time":"2013-05-24T01:08:03Z","timestamp":1369357683000},"page":"555-561","source":"Crossref","is-referenced-by-count":96,"title":["Is Fidaxomicin Worth the Cost? An Economic Analysis"],"prefix":"10.1093","volume":"57","author":[{"given":"Sarah M.","family":"Bartsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Umscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,5,23]]},"reference":[{"key":"key\n\t\t\t\t20170623071046_CIT346C1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1469-0691.2011.03571.x","article-title":"The economic burden of Clostridium difficile","volume":"18","author":"McGlone","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170623071046_CIT346C2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","article-title":"Clostridium difficile\u2014more difficult than ever","volume":"359","author":"Kelly","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623071046_CIT346C3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MAJ.0b013e3181e939d8","article-title":"Clostridium difficile infection","volume":"340","author":"Heinlen","year":"2010","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t20170623071046_CIT346C4","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0924-8579(09)70014-7","article-title":"Recurrent Clostridium difficile infection: causality and therapeutic approaches","volume":"33","author":"Johnson","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170623071046_CIT346C5","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/521860","article-title":"Treatment of Clostridium difficile infection","volume":"46","author":"Gerding","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/eri.10.28","article-title":"Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance","volume":"8","author":"Shah","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20170623071046_CIT346C7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/eri.11.53","article-title":"Fidaxomicin: first-in-class macrocyclic antibiotic","volume":"9","author":"Mullane","year":"2011","journal-title":"Expert Rev Anti-Infective Ther"},{"key":"key\n\t\t\t\t20170623071046_CIT346C8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623071046_CIT346C9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2009.02.073","article-title":"Clostridium difficile infection caused by the epidemic BI\/NAP1\/027 strain","volume":"136","author":"O'Connor","year":"2009","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170623071046_CIT346C11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/MOG.0b013e3283411634","article-title":"Update on Clostridium difficile infection","volume":"27","author":"O'Donoghue","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"key\n\t\t\t\t20170623071046_CIT346C12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623071046_CIT346C13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.cgh.2009.05.018","article-title":"Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting","volume":"7","author":"Cloud","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"suppl 6","key":"key\n\t\t\t\t20170623071046_CIT346C14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170623071046_CIT346C15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhin.2009.10.016","article-title":"Economic healthcare costs of Clostridium difficile infection: a systematic review","volume":"74","author":"Ghantoji","year":"2010","journal-title":"J Hosp Infect"},{"key":"key\n\t\t\t\t20170623071046_CIT346C16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1469-0691.2011.03571.x","article-title":"The economic burden of Clostridium difficile","volume":"18","author":"McGlone","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20170623071046_CIT346C17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1086\/592981","article-title":"Review of current literature on the economic burden of Clostridium difficile infection","volume":"30","author":"Dubberke","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20170623071046_CIT346C18","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s10096-012-1681-z","article-title":"The potential economic value of screening hospital admissions for Clostridium difficile","volume":"31","author":"Bartsch","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1086\/501553","article-title":"Recurrent Clostridium difficile disease: epidemiology and clinical characteristics","volume":"20","author":"McFarland","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 2","key":"key\n\t\t\t\t20170623071046_CIT346C20","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/cis335","article-title":"Burden of Clostridium difficile on the healthcare system","volume":"55","author":"Dubberke","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C21","doi-asserted-by":"crossref","first-page":"839","DOI":"10.7326\/0003-4819-155-12-201112200-00007","article-title":"Comparative effectiveness of Clostridium difficile treatments: a systematic review","volume":"155","author":"Drekonja","year":"2011","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170623071046_CIT346C22","volume-title":"Xpert C. difficile\/Epi brochure","author":"Cepheid"},{"key":"key\n\t\t\t\t20170623071046_CIT346C23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1086\/649213","article-title":"Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality","volume":"50","author":"Miller","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C24","doi-asserted-by":"crossref","first-page":"e1812","DOI":"10.1371\/journal.pone.0001812","article-title":"Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study","volume":"3","author":"Morgan","year":"2008","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170623071046_CIT346C25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infections Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20170623071046_CIT346C26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1377\/hlthaff.19.2.92","article-title":"Are pharmaceuticals cost-effective? A review of the evidence","volume":"19","author":"Neumann","year":"2000","journal-title":"Health Aff"},{"key":"key\n\t\t\t\t20170623071046_CIT346C27","volume-title":"HCUP facts and figures: statistics on hospital-based care in the United States, 2009","author":"United States Department of Health and Human Services"},{"key":"key\n\t\t\t\t20170623071046_CIT346C28","volume-title":"576. Incidence and insights into C. difficile infection epidemiology","author":"Lessa","year":"2012"},{"key":"key\n\t\t\t\t20170623071046_CIT346C29","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2146\/ajhp110371","article-title":"Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection","volume":"69","author":"Crawford","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t20170623071046_CIT346C30","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1007\/BF03261906","article-title":"Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price","volume":"32","author":"Sclar","year":"2012","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t20170623071046_CIT346C31","volume-title":"Pharmacy's fundamental reference. Red Book.","year":"2010"},{"key":"key\n\t\t\t\t20170623071046_CIT346C32","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1012413","article-title":"Host and pathogen factors for Clostridium difficile infection and colonization","volume":"365","author":"Loo","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170623071046_CIT346C33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/588293","article-title":"Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin","volume":"47","author":"Al-Nassir","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C34","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s10096-011-1477-6","article-title":"Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency","volume":"31","author":"Boone","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1086\/510391","article-title":"A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec","volume":"44","author":"Hubert","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C36","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/JCM.02446-10","article-title":"Comparison of strain typing results for Clostridium difficile isolated from North America","volume":"49","author":"Tenover","year":"2011","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170623071046_CIT346C37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(05)67420-X","article-title":"Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe","volume":"366","author":"Warney","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170623071046_CIT346C38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficle-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170623071046_CIT346C39","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"key":"key\n\t\t\t\t20170623071046_CIT346C40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.urology.2005.04.028","article-title":"Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?","volume":"66","author":"Ramsey","year":"2005","journal-title":"Urology"},{"key":"key\n\t\t\t\t20170623071046_CIT346C41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.ju.0000165569.48372.4c","article-title":"The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing agonist in men with metastatic prostate cancer","volume":"174","author":"Penson","year":"2005","journal-title":"J Urol"},{"key":"key\n\t\t\t\t20170623071046_CIT346C42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hec.4730030305","article-title":"A cost utility analysis of treatment options for gallstone disease: methodological issues and results","volume":"3","author":"Cook","year":"1994","journal-title":"Health Econ"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/57\/4\/555\/17854272\/cit346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T17:07:55Z","timestamp":1503421675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/cit346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,23]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,5,23]]},"published-print":{"date-parts":[[2013,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cit346","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5,23]]}}}